498 related articles for article (PubMed ID: 15696306)
1. Role of beta-lactam agents in the treatment of community-acquired pneumonia.
Garau J
Eur J Clin Microbiol Infect Dis; 2005 Feb; 24(2):83-99. PubMed ID: 15696306
[TBL] [Abstract][Full Text] [Related]
2. Short-course beta-lactam treatment for community-acquired pneumonia.
Stralin K; Sjöberg L; Holmberg H
Clin Infect Dis; 2004 Mar; 38(5):766-7. PubMed ID: 14986269
[No Abstract] [Full Text] [Related]
3. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
4. Decrease in drug resistance in pneumococcal community-acquired pneumonia.
Obando I; Arroyo L; Sanchez-Tatay D
Chest; 2007 Jul; 132(1):359; author reply 359-60. PubMed ID: 17625101
[No Abstract] [Full Text] [Related]
5. [In vitro resistance rates of Streptococcus pneumoniae and Haemophilus influenzae clinical isolates to the antibiotics used in therapy].
Uncu H; Colakoğlu S; Turunç T; Demiroğlu YZ; Arslan H
Mikrobiyol Bul; 2007 Jul; 41(3):441-6. PubMed ID: 17933256
[TBL] [Abstract][Full Text] [Related]
6. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
Feldman C
J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
[TBL] [Abstract][Full Text] [Related]
8. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The viewpoint of the pneumologist].
Poirier R
Presse Med; 1998 Sep; 27 Suppl 4():14-5. PubMed ID: 9798478
[No Abstract] [Full Text] [Related]
9. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
Sunakawa K; Farrell DJ
Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316
[TBL] [Abstract][Full Text] [Related]
10. Penicillin resistance in pneumococcal pneumonia. Antibiotics with low resistance potential are effective and pose less risk.
Cunha BA
Postgrad Med; 2003 Jan; 113(1):42-4, 47-8, 52-4. PubMed ID: 12545592
[TBL] [Abstract][Full Text] [Related]
11. [Antibiotic resistance of S. pneumoniae and H. influenzae strains isolated from patients with community acquired respiratory tract infections. BACTRO multicenter, multidisciplinary study].
Tudose C; Bumbăcea D; Bogdan M;
Pneumologia; 2011; 60(1):30-5. PubMed ID: 21548198
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
13. [Guidelines for treatment of pneumonia in intensive care units].
Emmi V
Infez Med; 2005; Suppl():7-17. PubMed ID: 16801748
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
Raz-Pasteur A; Shasha D; Paul M
Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
16. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
Segreti J; House HR; Siegel RE
Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
[TBL] [Abstract][Full Text] [Related]
17. [New quinolones for the treatment of community-acquired pneumonia--contra].
Egger M
Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
[No Abstract] [Full Text] [Related]
18. The hospitalist perspective on treatment of community-acquired bacterial pneumonia.
Amin AN; Cerceo EA; Deitelzweig SB; Pile JC; Rosenberg DJ; Sherman BM
Postgrad Med; 2014 Mar; 126(2):18-29. PubMed ID: 24685965
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic Resistance in Community-Acquired Pneumonia Pathogens.
Wunderink RG; Yin Y
Semin Respir Crit Care Med; 2016 Dec; 37(6):829-838. PubMed ID: 27960207
[TBL] [Abstract][Full Text] [Related]
20. [Discussions on PRSP and BLNAR].
Tajima T; Meguro H; Akita H; Iwata T
Jpn J Antibiot; 2001 May; 54 Suppl B():103; discussion 104-6. PubMed ID: 12638161
[No Abstract] [Full Text] [Related]
[Next] [New Search]
